Celecoxib pathways: pharmacokinetics and pharmacodynamics.
about
Radiochemistry on electrodes: Synthesis of an 18F-labelled and in vivo stable COX-2 inhibitor.Drug-gene interactions: inherent variability in drug maintenance dose requirementsComparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis.Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee.Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with SulfasalazineRibonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysisCytochrome P450 interactions and clinical implication in rheumatology.New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.Celecoxib-induced increase in cytosolic Ca(2+) levels and apoptosis in HA59T human hepatoma cells.Cancer cell killing by Celecoxib: reality or just in vitro precipitation-related artifact?A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors.Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS.Effect of antibiotics and NSAIDs on cyclooxygenase-2 in the enamel mineralization.Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level.
P2860
Q33626578-39B05A35-602F-4137-B95E-ADF9B0DE4F45Q34154939-36A5C363-F9F5-457A-BC4C-92647716E40BQ35642358-1A19730E-00D0-4AEF-BF3B-84AF74AF0425Q35844016-32328111-1EA7-48A1-8F18-B446E5D6C765Q36585257-FE50A1A7-302B-45A8-9316-A12550ABD857Q36868936-20C262EF-9C09-49F0-B67D-D8F2AB1232E6Q38219868-8B5F4877-52D3-41CE-B3B2-7635AE2AD75FQ38550876-A9E8E0A4-B733-4D8A-9322-F35C8C95235BQ38980297-6B6BF1F4-7E29-4B17-BF1B-4FE371ACB094Q39214848-E0281407-B515-4483-8E3C-5C4CD41C4924Q40062073-D0D0A00B-C6D7-4A97-88B5-27D5CB679773Q46446006-A3143D70-17EB-4679-84AC-512BE7420247Q47843202-CB006C81-87EA-4962-A10A-E4C13788899BQ48129186-B3F8D01A-5F73-4919-87D7-09DD885CAECFQ52728084-26ED1F0D-47B5-444F-8B7C-D4FFCDED1C2DQ55531057-A91BA67C-71E8-45DD-A2CD-3E76A8EAC5E6
P2860
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
@ast
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
@en
type
label
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
@ast
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
@en
prefLabel
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
@ast
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
@en
P2093
P2860
P1476
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
@en
P2093
Caroline F Thorn
Monica M Bertagnolli
Teri E Klein
Tilo Grosser
P2860
P304
P356
10.1097/FPC.0B013E32834F94CB
P50
P577
2012-04-01T00:00:00Z